{"id":37123,"date":"2022-12-12T00:00:44","date_gmt":"2022-12-12T08:00:44","guid":{"rendered":"https:\/\/vermont.salk.edu\/?post_type=disclosure&p=37123"},"modified":"2024-01-30T14:19:03","modified_gmt":"2024-01-30T22:19:03","slug":"salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice","status":"publish","type":"disclosure","link":"https:\/\/www.salk.edu\/zh\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/","title":{"rendered":"\u7d22\u5c14\u514b\u79d1\u5b66\u5bb6\u5f00\u53d1\u51fa\u4e00\u79cd\u80fd\u9006\u8f6c\u5c0f\u9f20\u80a0\u9053\u708e\u75c7\u7684\u5316\u5408\u7269"},"content":{"rendered":"

LA JOLLA\u2014A drug developed by Salk Institute researchers acts like a master reset switch in the intestines. The compound, called FexD, has previously been found to lower cholesterol, burn fat, and ward off colorectal cancer in mice. Now, the team reports in Proceedings of the National Academy of Sciences<\/em><\/a> on December 12, 2022, that FexD can also prevent and reverse intestinal inflammation in mouse models of inflammatory bowel disease.<\/p>\n

\"Salk
Salk researchers discovered the compound FexD can treat intestinal inflammation in mice. Mice with symptoms similar to inflammatory bowel disease had changes to the cells lining their intestines (left) that were reversed with treatment (right).
Click here<\/a> for a high-resolution image.
Credit: Salk Institute<\/figcaption><\/figure>\n

\u201cThe Salk-developed drug FexD provides a new way to restore balance to the digestive system and treat inflammatory diseases that are currently very difficult to manage,\u201d says senior author and Salk Professor\u00a0\u7f57\u7eb3\u5fb7\u00b7\u57c3\u6587\u65af<\/a>, director of Salk\u2019s Gene Expression Laboratory and March of Dimes Chair in Molecular and Developmental Biology.<\/p>\n

Inflammatory bowel disease (IBD), which includes both Crohn\u2019s disease and ulcerative colitis, is characterized by an excess of immune cells and inflammatory signaling molecules known as cytokines in the gut. Existing treatments, which mostly work by either suppressing the entire immune system or by targeting individual cytokines, are only effective for some patients and carry a host of side effects.<\/p>\n

For more than two decades, Evans\u2019 lab has studied Farnesoid X receptor (FXR), a master regulator protein that senses the bile acids delivered to the digestive system to help digest food and absorb nutrients. When FXR detects a shift in bile acids at the beginning of a meal, it prepares the body for an influx of food by flipping on and off dozens of cellular programs related to digestion, blood sugar, and fat metabolism.<\/p>\n

\"From
From left: Ruth Yu, Ye Zheng, Michael Downes, Ron Evans, Yuwenbin Li, and Annette Atkins
Click here<\/a> for a high-resolution image.
Credit: Salk Institute<\/figcaption><\/figure>\n

In 2015, Evans and his colleagues developed a pill called fexaramine that activates FXR in the gut. The pill, they initially showed, can stop weight gain and control blood sugar<\/a> in mice. In 2019, they showed that FexD\u2014an updated version of fexaramine\u2014also prevented cancer-associated changes to stem cells<\/a> in the gut. Their work suggested that FXR also played a role in regulating inflammation.<\/p>\n

\u201cEvery time you eat, you\u2019re causing small amounts of inflammation in your gut as your intestinal cells encounter new molecules. FXR makes sure inflammation stays under control during normal feeding,\u201d says Senior Staff Scientist Michael Downes, co-corresponding\u00a0author of the new paper.<\/p>\n

In the new work, Evans\u2019 group discovered that activating FXR can be used to ease symptoms in inflammation-driven diseases. When the researchers gave mice with IBD a daily dose of oral FexD, either before or after the onset of intestinal inflammation, the drug prevented or treated the inflammation. By activating FXR, FexD reduced the infiltration of a class of highly inflammatory immune cells called innate lymphoid cells. In turn, levels of cytokines already implicated in IBD decreased to levels normally seen in healthy mice.<\/p>\n

\"Ting
Ting Fu
Click here<\/a> for a high-resolution image.
Credit: Salk Institute<\/figcaption><\/figure>\n

\u201cWhen we activate FXR, we restore appropriate signaling pathways in the gut, bringing things back to a homeostatic level,\u201d says Senior Research Scientist Annette Atkins, co-author of the study.<\/p>\n

Since FXR acts more like a reset button than an off switch for the immune system, cytokines are not completely blocked by FexD. This means that the immune system continues functioning in a normal way after a dose of FexD. The compound still must be optimized for use in humans and tested in clinical trials, but the researchers say their findings provide important information about the complex links between gut health and inflammation and could eventually lead to an IBD therapeutic.<\/p>\n

\u201cIn people with IBD, our strategy could potentially be very effective at preventing flare-ups and as a long-term maintenance drug,\u201d says first author Ting Fu, previously a postdoctoral fellow at Salk and now an assistant professor at the University of Wisconsin-Madison.<\/p>\n

Other authors of the paper include Yuwenbin Li, Tae Gyu Oh, Fritz Cayabyab, Nanhai He, Qin Tang, Morgan Truitt, Paul Medina, Mingxiao He, Ruth T. Yu, and Ye Zheng of Salk; and Sally Coulter and Christopher Liddle of the University of Sydney.<\/p>\n

The work was supported in part by the National Institutes of Health (DK057978, HL105278 and HL088093), the National Cancer Institute (CA014195), the National Health and Medical Research Council of Australia (grant 1087297) the Leona M. and Harry B. Helmsley Charitable Trust (2017PG-MED001), an SWCRF Investigator Award, \u00a0a Hewitt Medical Foundation Fellowship, a Salk Alumni Fellowship, a Crohn’s & Colitis Foundation (CCFA) Visiting IBD Research Fellowship, a Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (SU2C-AACR-DT-20-16), the Howard Hughes Medical Institute, the NOMIS Foundation, and the National Institute of Environmental Health Sciences (P42ES010337).<\/p>","protected":false},"featured_media":37143,"template":"","faculty":[91,56],"disease-research":[447,122],"class_list":["post-37123","disclosure","type-disclosure","status-publish","has-post-thumbnail","hentry","faculty-ronald-evans","faculty-ye-zheng","disease-research-colorectal-cancer","disease-research-immune-system-biology"],"acf":[],"yoast_head":"\nSalk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.salk.edu\/zh\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA\u2014A drug developed by Salk Institute researchers acts like a master reset switch in the intestines. The compound, called FexD, has previously been found to lower cholesterol, burn fat, and ward off colorectal cancer in mice. Now, the team reports in Proceedings of the National Academy of Sciences on December 12, 2022, that FexD can also prevent and reverse intestinal inflammation in mouse models of inflammatory bowel disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.salk.edu\/zh\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/\" \/>\n<meta property=\"og:site_name\" content=\"Salk Institute for Biological Studies\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-30T22:19:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-767.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"767\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/\",\"name\":\"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Histology-v1-767.jpg\",\"datePublished\":\"2022-12-12T08:00:44+00:00\",\"dateModified\":\"2024-01-30T22:19:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/#breadcrumb\"},\"inLanguage\":\"zh-CN\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Histology-v1-767.jpg\",\"contentUrl\":\"https:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/Histology-v1-767.jpg\",\"width\":767,\"height\":767,\"caption\":\"Salk researchers discovered the compound FexD can treat intestinal inflammation in mice. Mice with symptoms similar to inflammatory bowel disease had changes to the cells lining their intestines (left) that were reversed with treatment (right).\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/news-release\\\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.salk.edu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salk scientists develop compound that reverses gut inflammation in mice\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#website\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"name\":\"Salk Institute for Biological Studies\",\"description\":\"The Power of Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.salk.edu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-CN\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#organization\",\"name\":\"Salk Institute for Biological Studies\",\"url\":\"https:\\\/\\\/www.salk.edu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-CN\",\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"contentUrl\":\"http:\\\/\\\/www.salk.edu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/salk_logo_696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Salk Institute for Biological Studies\"},\"image\":{\"@id\":\"https:\\\/\\\/www.salk.edu\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.salk.edu\/zh\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/","og_locale":"zh_CN","og_type":"article","og_title":"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies","og_description":"LA JOLLA\u2014A drug developed by Salk Institute researchers acts like a master reset switch in the intestines. The compound, called FexD, has previously been found to lower cholesterol, burn fat, and ward off colorectal cancer in mice. Now, the team reports in Proceedings of the National Academy of Sciences on December 12, 2022, that FexD can also prevent and reverse intestinal inflammation in mouse models of inflammatory bowel disease.","og_url":"https:\/\/www.salk.edu\/zh\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/","og_site_name":"Salk Institute for Biological Studies","article_modified_time":"2024-01-30T22:19:03+00:00","og_image":[{"width":767,"height":767,"url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-767.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/","url":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/","name":"Salk scientists develop compound that reverses gut inflammation in mice - Salk Institute for Biological Studies","isPartOf":{"@id":"https:\/\/www.salk.edu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/#primaryimage"},"image":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/#primaryimage"},"thumbnailUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-767.jpg","datePublished":"2022-12-12T08:00:44+00:00","dateModified":"2024-01-30T22:19:03+00:00","breadcrumb":{"@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/#breadcrumb"},"inLanguage":"zh-CN","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/"]}]},{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/#primaryimage","url":"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-767.jpg","contentUrl":"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-767.jpg","width":767,"height":767,"caption":"Salk researchers discovered the compound FexD can treat intestinal inflammation in mice. Mice with symptoms similar to inflammatory bowel disease had changes to the cells lining their intestines (left) that were reversed with treatment (right)."},{"@type":"BreadcrumbList","@id":"https:\/\/www.salk.edu\/news-release\/salk-scientists-develop-compound-that-reverses-gut-inflammation-in-mice\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.salk.edu\/"},{"@type":"ListItem","position":2,"name":"Salk scientists develop compound that reverses gut inflammation in mice"}]},{"@type":"WebSite","@id":"https:\/\/www.salk.edu\/#website","url":"https:\/\/www.salk.edu\/","name":"\u7d22\u5c14\u514b\u751f\u7269\u7814\u7a76\u6240","description":"The Power of Science","publisher":{"@id":"https:\/\/www.salk.edu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.salk.edu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-CN"},{"@type":"Organization","@id":"https:\/\/www.salk.edu\/#organization","name":"\u7d22\u5c14\u514b\u751f\u7269\u7814\u7a76\u6240","url":"https:\/\/www.salk.edu\/","logo":{"@type":"ImageObject","inLanguage":"zh-CN","@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/","url":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","contentUrl":"http:\/\/www.salk.edu\/wp-content\/uploads\/2023\/03\/salk_logo_696.jpg","width":696,"height":696,"caption":"Salk Institute for Biological Studies"},"image":{"@id":"https:\/\/www.salk.edu\/#\/schema\/logo\/image\/"}}]}},"ACF":{"hero":"https:\/\/www.salk.edu\/wp-content\/uploads\/2022\/12\/Histology-v1-header.jpg","line_1":"Salk scientists develop compound that reverses gut inflammation in mice","line_2":"By targeting a molecule that keeps order in the gut, the new therapeutic has the potential to treat inflammatory bowel disease ","poster_quote":"","paper_url":"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2213041119","journal_title":"Proceedings of the National Academy of Sciences","paper_author_list":"Ting Fu, Yuwenbin Li, Tae Gyu Oh, Fritz Cayabyab, Nanhai He, Qin Tang, Sally Coulter, Morgan Truitt, Paul Medina, Mingxiao He, Ruth T. Yu, Annette Atkins, Ye Zheng, Christopher Liddle, Michael Downes, and Ronald M. Evans","doi":"10.1073\/pnas.2213041119","paper_title":"FXR mediates ILC-intrinsic responses to intestinal inflammation","subhead":"By targeting a molecule that keeps order in the gut, the new therapeutic has the potential to treat inflammatory bowel disease ","home_photo":"","listing_photo":"","legacy_boilerplate":[],"hide_boilerplate":[],"disable_date":false,"listing_excerpt":"","descriptive_blurb":"","has_journal_cover":false,"og_image_override":false,"gallery":false},"_links":{"self":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/37123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure"}],"about":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/types\/disclosure"}],"version-history":[{"count":10,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/37123\/revisions"}],"predecessor-version":[{"id":37273,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disclosure\/37123\/revisions\/37273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/media\/37143"}],"wp:attachment":[{"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/media?parent=37123"}],"wp:term":[{"taxonomy":"faculty","embeddable":true,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/faculty?post=37123"},{"taxonomy":"disease-research","embeddable":true,"href":"https:\/\/www.salk.edu\/zh\/wp-json\/wp\/v2\/disease-research?post=37123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}